Here’s Why Eli Lilly and Company (LLY) Rose in Q4

Baron Funds, an investment management company, released its “Baron Health Care Fund” fourth quarter 2022 investor letter. A copy of the same can be downloaded here. In the fourth quarter, the fund increased by 9.08% (Institutional Shares) compared to an 11.54% gain for the Russell 3000 Health Care Index and a 7.56% gain for the S&P 500 Index. The fund fell 16.90% in 2022, compared to a 6.10% decline for the Russell 3000 Health Care Index and an 18.11% decline for the S&P 500 Index. Factors like cash exposure in the up-market, adverse stock selection, and differences in sub-industry exposures led the fund to underperform in the quarter relative to its benchmark. In addition, please check the fund’s top five holdings to know its best picks in 2022.

Baron Funds highlighted stocks like Eli Lilly and Company (NYSE:LLY) in the Q4 2022 investor letter. Headquartered in Indianapolis, Indiana, Eli Lilly and Company (NYSE:LLY) is a pharmaceuticals company. On January 27, 2023, Eli Lilly and Company (NYSE:LLY) stock closed at $342.10 per share. One-month return of Eli Lilly and Company (NYSE:LLY) was -6.49%, and its shares gained 39.41% of their value over the last 52 weeks. Eli Lilly and Company (NYSE:LLY) has a market capitalization of $325.056 billion.

Baron Funds made the following comment about Eli Lilly and Company (NYSE:LLY) in its Q4 2022 investor letter:

“Eli Lilly and Company (NYSE:LLY) is a large-cap pharmaceutical company. Shares increased on investor optimism about Lilly’s new product pipeline, which includes Mounjaro for diabetes and obesity and Donanemab for Alzheimer’s disease. We continue to think Lilly has a healthy base business with limited near-term patent expirations, a strong pipeline, and potential for significant margin expansion, which should translate to strong revenue and earnings growth over at least the next five years.”

Eli Lilly and Company (NYSE:LLY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 75 hedge fund portfolios held Eli Lilly and Company (NYSE:LLY) at the end of the third quarter, which was 70 in the previous quarter.

We discussed Eli Lilly and Company (NYSE:LLY) in another article and shared the best dividend stocks to buy and hold. In addition, please check out our hedge fund investor letters Q4 2022 page for more investor letters from hedge funds and other leading investors.

Suggested Articles:

• Top 25 Agrochemical Companies in the World
• 10 Dumbest Companies to Invest In
• 12 Cash Rich Dividend Stocks To Buy

Disclosure: None. This article is originally published at Insider Monkey.